ISU Abxis Co., Ltd. is a biopharmaceutical company based in Seongnam, South Korea. Founded in 2001, the company is a subsidiary of ISU Group and specializes in the development and manufacturing of therapeutic antibodies for the treatment of incurable diseases such as cancer and rare diseases. Their product portfolio includes Abciximab, Clotinab®, Abcertin®, and Fabagal®. In addition to their pharmaceutical products, ISU Abxis also operates in the diagnostic business division, providing diagnostic kits and reagents. The company is listed on the Korea Stock Exchange under the ticker symbol 086890.KR.
Headquarters
5F C-Dong 22 No.712 Daewangpangyo-Road, Bundang-Gu, Seongnam-Si
Seongnam; Gyeonggi;
Contact Details: Purchase the ISU Abxis Co.,Ltd. report to view the information.
Website: http://www.abxis.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service